Metastatic HER2-Positive Breast Cancer

Metastatic HER2-Positive Breast Cancer overview

Metastatic HER2-Positive Breast Cancer is one type of breast cancer in which test for breast cancer cells shows a positive sign for a protein receptor known as human epidermal growth factor receptor 2. The usual function of this protein is to regulate a healthy breast cell how it grows, divides, and repairs itself.

However, when there is a mutation in the gene that controls the HER2 protein, also called as erythroblastosis oncogene B (ERBB2) gene, the body produces too many HER2 receptors, which leads to uncontrollable breast cell growth and division. Some of the most common symptoms of Metastatic HER2-Positive Breast Cancer are breast swelling, change in the shape of breast, skin irritation or dimpling, pain in the breast, redness or thickness of the breast skin.

A HER2-positive breast cancer diagnosis is confirmed by tests, such as the IHC test, the FISH test, the SPOT-Light HER2 CISH, and the Inform HER2 Dual ISH tests. These tests utilize antibodies or DNA to stain the cancer cells.

Metastatic HER2-Positive Breast Cancer Epidemiology

Breast cancer total incident population in the 7MM was found to be 626,867 in 2017, which is anticipated to rise during the study period [2017–2028]. A higher Breast cancer incidence was observed in the United States. Among the EU-5 countries, Germany ranked the first, followed by Italy, and France, while Spain witnessed the least number of breast cancer cases in 2017.

Metastatic HER2-Positive Breast Cancer Market Scenario

The market comprises a variety of options for the Metastatic HER-2 Positive Breast Cancer treatment. It is mainly categorized into pharmacological and non-pharmacological therapies. A medical oncologist generally prescribes systemic therapies. Common ways to give systemic therapies include an intravenous (IV) tube or can be given orally.

The systemic therapies used for metastatic breast cancer include Targeted Therapy and Hormonal therapy (Endocrine therapy). 

On the other hand, hormonal therapy market also includes Aromatase Inhibitors that reduce the production of estrogen by inhibiting the aromatase enzyme activity in peripheral tissues and within the tumour microenvironment. The market landscape of aromatase inhibitors mainly depends on three agents, Exemestane (Pharmacia & Upjohn Company), Anastrozole (AstraZeneca), and Letrozole (Novartis Pharmaceuticals).

Key players that are producing drugs for Metastatic HER-2 Positive Breast Cancer such as MacroGenics, Puma Biotechnology, Seattle Genetics, Jiangsu HengRui Medicine, Prestige Biopharma Pte Ltd, EirGenix, Inc., and others are involved in developing therapies.